Your browser doesn't support javascript.
loading
Pulsed focused ultrasound enhances the therapeutic effect of mesenchymal stromal cell-derived extracellular vesicles in acute kidney injury.
Ullah, Mujib; Liu, Daniel D; Rai, Sravanthi; Razavi, Mehdi; Concepcion, Waldo; Thakor, Avnesh S.
Afiliación
  • Ullah M; Interventional Regenerative Medicine and Imaging Laboratory, Department of Radiology, Stanford University, Palo Alto, CA, 94304, USA.
  • Liu DD; Interventional Regenerative Medicine and Imaging Laboratory, Department of Radiology, Stanford University, Palo Alto, CA, 94304, USA.
  • Rai S; Interventional Regenerative Medicine and Imaging Laboratory, Department of Radiology, Stanford University, Palo Alto, CA, 94304, USA.
  • Razavi M; Interventional Regenerative Medicine and Imaging Laboratory, Department of Radiology, Stanford University, Palo Alto, CA, 94304, USA.
  • Concepcion W; Interventional Regenerative Medicine and Imaging Laboratory, Department of Radiology, Stanford University, Palo Alto, CA, 94304, USA.
  • Thakor AS; Interventional Regenerative Medicine and Imaging Laboratory, Department of Radiology, Stanford University, Palo Alto, CA, 94304, USA. asthakor@stanford.edu.
Stem Cell Res Ther ; 11(1): 398, 2020 09 14.
Article en En | MEDLINE | ID: mdl-32928310
ABSTRACT

BACKGROUND:

Acute kidney injury (AKI) is characterized by rapid failure of renal function and has no curative therapies. Mesenchymal stromal cell (MSC)-derived extracellular vesicles (EVs) are known to carry therapeutic factors, which have shown promise in regenerative medicine applications, including AKI. However, there remains an unmet need to optimize their therapeutic effect. One potential avenue of optimization lies in pulsed focused ultrasound (pFUS), where tissues-of-interest are treated with sound waves. pFUS has been shown to enhance MSC therapy via increased cell homing, but its effects on cell-free EV therapy remain largely unexplored.

METHODS:

We combine pFUS pretreatment of the kidney with MSC-derived EV therapy in a mouse model of cisplatin-induced AKI.

RESULTS:

EVs significantly improved kidney function, reduced injury markers, mediated increased proliferation, and reduced inflammation and apoptosis. While pFUS did not enhance EV homing to the kidney, the combined treatment resulted in a superior therapeutic effect compared to either treatment alone. We identified several molecular mechanisms underlying this synergistic therapeutic effect, including upregulation of proliferative signaling (MAPK/ERK, PI3K/Akt) and regenerative pathways (eNOS, SIRT3), as well as suppression of inflammation.

CONCLUSION:

Taken together, pFUS may be a strategy for enhancing the therapeutic efficacy of MSC-derived EV treatment for the treatment of AKI.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Lesión Renal Aguda / Células Madre Mesenquimatosas / Vesículas Extracelulares / Ondas Ultrasónicas Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Stem Cell Res Ther Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Lesión Renal Aguda / Células Madre Mesenquimatosas / Vesículas Extracelulares / Ondas Ultrasónicas Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Stem Cell Res Ther Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos